Earnings Per Share

EPS (Diluted)

Veradermics EPS (Diluted) increased by 93.3% to $-1.32 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 93.3%, from $-19.79 to $-1.32. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement
SectionEarnings Per Share
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2024
Last reportedQ1 2026May 12, 2026

How to read this metric

Higher values indicate stronger profitability even when accounting for potential share dilution.

Detailed definition

Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...

Peer comparison

Used by all public companies to provide a realistic view of earnings per share for investors.

Metric ID: eps_diluted

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q1 '26
Value-$9.26-$9.26-$9.26-$9.26-$19.79-$1.32
QoQ Change+0.0%+0.0%+0.0%-113.7%+93.3%
YoY Change-113.7%+93.3%
Range-$19.79-$1.32
CAGR-79.0%
Avg YoY Growth-10.2%
Median YoY Growth-10.2%

Frequently Asked Questions

What is Veradermics 's eps (diluted)?
Veradermics (MANE) reported eps (diluted) of $-1.32 in Q1 2026.
How has Veradermics 's eps (diluted) changed year-over-year?
Veradermics 's eps (diluted) increased by 93.3% year-over-year, from $-19.79 to $-1.32.
What does eps (diluted) mean?
Earnings per share calculated as if all potential shares were issued.